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ABSTRACT
Objective: The objective of this study was to develop an in situ ophthalmic gel of an anti-infective drug, moxifloxacin (MOX) hydrochloride (HCL), for 
sustained ocular delivery for the treatment of bacterial infections of the eye.
Results: Optimized formulation batch F7 (0.12% gelrite and 0.6% sodium alginate) was liquid before addition of simulated tear fluid (STF) and 
underwent rapid gelation on addition of STF and had given 84.05% cumulative drug release; the formulation was found to be clear, having good in situ 
gelling capacity, good antibacterial efficacy, having drug content 99.75%; optimized formulation was sterile and showed sustained drug release over 
8 h period as compared to marketed eye drop.
Conclusions: From the above results, we can concluded that 32 full factorial design and statistical models can be successfully used to optimize the 
formulations, and it was concluded that the trial batch F7 (0.12% gelrite and 0.6% sodium alginate) is the best formula (percentage cumulative drug 
release over 84.05%) and it is possible to formulate in situ ophthalmic gels of MOX HCL using gelrite in combination with sodium alginate for the 
treatment of various bacterial infections of the eyes.
Keywords: Moxifloxacin hydrochloride, Gelrite, Sodium alginate, In situ gel, In vitro diffusion, Rheological studies.
INTRODUCTION
Ophthalmic drug delivery is the most challenging and interesting area 
for upcoming pharmacists and formulation chemist due to unique 
anatomy and physiology of the eye. Eye drops that are conventional 
ophthalmic delivery systems often result in poor bioavailability and 
therapeutic response because high tear fluid turnover and dynamics 
cause rapid precorneal elimination of the drug. A high frequency of 
eye drop instillation is the main cause of patient non-compliance. 
Addition of excess drug in the formulation is an attempt to overcome 
bioavailability problem which is potentially dangerous if the drug 
solution drained from the eye is systemically absorbed from the 
nasolacrimal duct. Various other ophthalmic vehicles such as ointments, 
suspension, inserts, and aqueous gels have been developed to enhance 
the ophthalmic bioavailability. This ocular drug delivery system, 
however, has not been used frequently due to some disadvantages 
such as blurred vision from ointments or low patient compliance from 
inserts.
Above-mentioned problems can be overcome by the use of in situ 
gelling systems, a liquid dosage form suitable to be administered by 
instillation into the eye, which on exposure to physiological conditions, 
changes to the gel phase thus increase the precorneal residence 
time of the delivery system and enhance the ocular bioavailability. It 
comprises the ease of eye drop instillation and patient compliance as 
well as sustained release property that is described to intensify ocular 
bioavailability. The concept of in situ forming gels came into existence 
in the early 80s.
Depending on the method employed to cause sol to gel phase transition 
on the ocular surface, the following three types of systems have been 
recognized:
•	 pH-triggered	 -	 the	 polymers	 used	 in	 this	 system	 are	 pseudo-
latexes - carbomer (carbopol), cellulose acetate phthalate latex.
•	 Temperature	dependent	 -	 poloxamers	 (pluronic	 and	 tetronics),	
cellulose derivatives (methylcellulose and hydroxypropyl-
methylcellulose), xyloglucan.
•	 Ion-activated	induced	–	alginates	and	gelrite	(gellan	gum)	[1].
Moxifloxacin (MOX) hydrochloride (HCL) is a fourth-generation 
fluoroquinolone broad-spectrum antibacterial, Biopharmaceutical 
Classification System Class-I drug, having low ocular bioavailability and 
therapeutic response due to high tear fluid turn over and rapid precorneal 
elimination of ocular dosage form. Hence, the rationale is to increase the 
bioavailability and patient compliance of MOX by formulating ophthalmic 
in situ gel which gives better residence time using a combination of 
polymers (as a release retardant) and make it more effective.
The aim of present work is to design, develop, and evaluate in situ 
ophthalmic gel of an anti-infective drug (MOX HCL 0.5% w/v) for 
sustained ocular delivery using a combination of gelrite as gelling 
agent and sodium alginate as viscosifying agent which is used for the 
treatment of various infective diseases of the eye, to get better patient 
compliance by increasing residence time and bioavailability.
The formulation would be useful to treat external infections of the eye 




MOX HCL was purchased from Yarrow Chem Products Pvt., Ltd., Mumbai, 
Gelrite was provided by Yarrow Chem Products Pvt., Ltd., Mumbai. 
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i3.28086
Research Article
Method: In the present work the in situ gelling systems were prepared by ion exchange method with the help of various concentrations of gelling agent 
gelrite (0.08 g, 0.1 g and 0.12 g) and sodium alginate (0.6 g, 0.8 g and 1 g) as viscosity enhancer were added in the formulation; 9 formulations 
were prepared according to 32  factorial  designs and evaluated.  The responses were analyzed for the analysis of variance using Design-Expert 
version 10 software. Statistical models were generated for each response parameter.
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Sodium alginate was purchased from Thomas Baker (Chemicals) Pvt. 
Ltd., Mumbai, and all other ingredients were of analytical grade.
Methods
Selection of drug and polymers
MOX is a fourth-generation fluoroquinolone with expanded activity against 
Gram-positive, Gram-negative bacteria as well as atypical pathogens. MOX 
is the hydrochloride salt of a fluoroquinolone antibacterial antibiotic. In 
common with quinolone antibiotics, the bactericidal action of MOX results 
from inhibition of the topoisomerase II (DNA gyrase) and topoisomerase 
IV required for bacterial DNA replication, transcription, repair, and 
recombination. Topoisomerase IV is the primary activity inhibited 
for many Gram-positive bacteria whereas DNA gyrase is the primary 
quinolone	target	in	many	Gram-negative	microbes	[2].
Determination of absorbance maxima of MOX by ultraviolet (UV) 
spectrophotometer
A	solution	of	MOX	containing	the	concentration	10	μg/ml	was	prepared	
in simulated tear fluid (STF) pH 7.4 and UV spectrum was taken using 
Shimadzu (UV-1800) double beam spectrophotometer. The solution 
was	scanned	in	the	range	of	200–400	nm	(Fig. 1).
Identification of MOX
Identification of MOX was carried out by Fourier-transform infrared 
(FTIR) spectrophotometer (Fig. 2).
Interaction studies [3]
The proper design and formulation of a dosage form require 
consideration of the physical, chemical, and biological characteristics of 
all drug substances and excipients to be used in the formulation of the 
product. The drug and excipients must be compatible with one another 
to produce a stable, efficacious, and safe product. The interaction 
study of prepared in situ gel formulations was carried out using IR 
spectroscopy following potassium bromide (KBr) dispersion method. 
The spectrum of a dried mixture of drug and KBr was then run followed 
by drug with excipients in the wavelength region between 4000 and 
400 cm−1 (Fig. 4).
The drug-polymer compatibility was confirmed by differential scanning 
calorimetric (DSC). Thermal characterization of pure drug and polymer 
mixture was performed with a calorimeter, which was carried out 
by heating drug and the physical mixture of the drug with polymers 
Fig. 1: Ultraviolet spectrum of moxifloxacin at 288.5
Fig. 2: Infrared spectra for pure moxifloxacin
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separately from 20°C to 300°C at the heating rate of 10°C/min in a 
nitrogen environment (Fig. 5).
Preparation of in situ gelling system
Factorial design [4,5]
A 32 randomized full factorial design was used in the present 
study. In this design, 2 factors were evaluated; each at 3 level and 
experimental trials were performed for all 9 possible combinations. 
The concentration of gelrite (X1) and concentration of sodium alginate 
(X2) was chosen as an independent variable in 32 full factorial designs, 
while percent cumulative drug release was taken as dependent variable 
(Table 1a-c and Fig. 13).
The formulation layout for the factorial design batches (F1-F9) is shown 
in Tables 2 and 3.
Procedure
A 32 factorial design was used for formulation design, gellan gum (gelrite) 
and sodium alginate were chosen as an independent factor. Their effect 
on dependent factors such as drug release and viscosity was observed. 
An aqueous solution of a varying concentration of gelrite and sodium 
alginate was prepared and evaluated for gelling capacity and viscosity to 
identify the compositions suitable for as an in situ gelling system. Polymer 
solution was prepared by dissolving required quantity of sodium chloride 
in deionized water followed by dispersing gelrite and sodium alginate 
Fig. 4: Infrared spectra of a physical mixture of moxifloxacin, gelrite, and sodium alginate
Table 1: ANOVA for response surface linear model. (a): ANOVA table (partial sum of squares - type III)
Source Sum of squares df Mean square F value p-value prob.>F Significant
Model 417.56 2 208.78 107.32 <0.0001
A-gelrite 346.56 1 346.56 178.14 <0.0001
B-sodium alginate 71.00 1 71.00 36.50 0.0009
Residual 11.67 6 1.95
Cor total 429.23 8
ANOVA: Analysis of variance
Fig. 3: Differential scanning calorimetric of hydrochloride
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in above solution and heat up to 90°C for 20 min followed by cooling to 
room temperature, drug solution was prepared by dissolving MOX in 
mixture of propylene glycol and deionized water (8:100), drug solution 
was mixed with polymer solution using a magnetic stirrer under constant 
stirring until a uniform solution was obtained. The pH of the formulation 
was then set to 4.4 using 0.1 N HCL. The prepared in situ gels were filled 
in glass vials closed with rubber closures and sealed with aluminum caps 
and	sterilized	by	autoclave	at	121°C	15	psi	for	20	mi	[4,5].
Evaluation of prepared in situ gelling system
Interaction studies [6]
IR spectra were taken using FTIR spectrophotometer (Jasco 4100). The 
pellets of drug and KBr were prepared by compressing the powders 
(Ratio of drug to KBr 1:100) at 20 psi on KBr press, and the spectra 
were	scanned	in	the	wave	number	range	of	4000–400	cm−1 FTIR study 
was carried on pure drug, physical mixture of drug and polymers, 
formulations to confirm the compatibility of drug with other excipients 
used in the preparation of in situ gels (Fig. 6).
Visual appearance and clarity [7]
Visual appearance and clarity were checked under fluorescent light 
against a white and black background for the presence of any particulate 
matter (Table 4).
pH [8]
The pH of the prepared in situ gelling system after addition of all the 
ingredients was measured using pH meter (Table 4).
In vitro gelation [8]
The gelling capacity of formulations was evaluated to identify the 
formulations suitable for use as in situ gelling systems. Gelling capacity 
was determined by mixing the formulation with STF in the proportion 
25:7 and examined visually.
The composition of STF was sodium chloride (0.68 g), sodium 
bicarbonate (0.22 g), calcium chloride dehydrate (0.008), potassium 
chloride (0.14 g), and double distilled water quantity sufficient up 
to100 g. Physiological pH (7.4±0.2) was adjusted by adding the required 
amount of 0.1 N HCl/NaOH (Table 4).
Rheological studies [8]
The viscosity of the instilled formulation is an important factor 
in determining residence time of drug in the eye. The prepared 
solutions were allowed to gel in the STF, and then the viscosity 
determination was carried out using Brookfield viscometer DV-
II+PRO model, angular velocity range from 1 to 100 rpm. Viscosity of 
the formulations increased with increase in polymer concentration. 
The hierarchy of shear rate was reversed and an average of three 
readings was used to calculate viscosity (Tables 5 and 6 and 
Figs. 8 and 9).
Sterility testing [8,9]
Sterility testing is intended for detecting that the presence of a viable 
form of microorganisms and was performed for aerobic and anaerobic 
bacteria and fungi using fluid thioglycolate medium and soybean 
casein digest medium, respectively, as per the Indian Pharmacopoeia 
(Table 7).
Drug content analysis [7,8]
Fig. 5: Thermal analysis of a physical mixture of moxifloxacin+gelrite+sodium alginate











SD: Standard deviation, ANOVA: Analysis of variance, Bayesian information 
criterion (BIC), and Akaike’s information criterion
Table 1c: Parameters of ANOVA (b)
Factor Coefficient estimate df Standard error 95% CI low 95% CI high VIF
Intercept 89.24 1 0.46 88.10 90.38
A-gelrite −7.60 1 0.57 −8.99 −6.21 1.00
B-sodium alginate −3.44 1 0.57 −4.83 −2.05 1.00
CI: Confidence interval, VIF: Variance inflation factor, ANOVA: Analysis of variance
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Estimation of MOX by spectrophotometric method
A simple and rapid method for estimation of MOX by UV 
spectrophotometric method was developed in STF. MOX in STF of pH 7.4 
shows	absorbance	maxima	(λmax) at 288.5 nm (Table 8 and Fig. 10).
In vitro release studies [8,10]
In vitro drug release from the formulations was studied by the diffusion 
cell. Here, the pH of the lacrimal fluid and the blinking rate of the eye 
were taken into consideration and were simulated. The procedure for 
standard calibration is the same as mentioned under drug content 
determination.
Comparative evaluation of marketed product with prepared 
in situ gels
In vitro release studies of the marketed formulation were carried 
out using bi-chambered donor receiver compartment model (Franz 
diffusion cell) using cellophane membrane soaked overnight in the 
receptor medium (STF pH 7.4). The diffusion medium was 12 ml 
Table 2: Amount of variables in 32 factorial design batches





Table 3: Contents of formulation
S. No Ingredients Concentration (% w/v)
F1 F2 F3 F4 F5 F6 F7 F8 F9
1 MOX HCL 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
2 Gelrite 0.08 0.08 0.08 0.1 0.1 0.1 0.12 0.12 0.12
3 Sodium alginate 0.6 0.8 1 0.6 0.8 1 0.6 0.8 1
4 Propylene glycol 8 8 8 8 8 8 8 8 8
5 Sodium chloride 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
6 0.1 N HCl Quantity sufficient to adjust to pH 4.4
7 Deionized water Quantity sufficient to 100 ml
MOX HCL: Moxifloxacin hydrochloride. *All quantities are expressed as % w/v
Table 4: Evaluation of visual appearance, clarity, pH, and drug content
Formulation code Visual appearance Clarity pH Gelling capacity Drug content (%)
F1 Translucent Clear 4.4±0.029 + 87.34±0.012
F2 Translucent Clear 4.4±0.014 + 78.11±0.01
F3 Translucent Clear 4.4±0.008 ++ 73.37±0.015
F4 Translucent Clear 4.4±0.014 + 90.17±0.12
F5 Translucent Clear 4.4±0.021 ++ 87.48±0.07
F6 Translucent Clear 4.4±0.04 +++ 81.14±0.05
F7 Translucent Clear 4.4±0.016 +++ 99.75±0.045
F8 Translucent Clear 4.4±0.163 +++ 95.93±0.024
F9 Translucent Clear 4.4±0.014 +++ 95.95±0.02
SD: Standard deviation (n±3). +Gels after a few min and dissolves rapidly, ++gelation immediate and remains for few h, +++Shows gelation immediate and remains for 
extended period
Table 5: Viscosity of the formulation (CPS) before gelation
Shear rate (RPM) F1±SD F2±SD F3±SD F4±SD F5±SD F6±SD F7±SD F8±SD F9±SD
1 39.1±0.121 42.3±0.063 50.1±0.304 63.1±0.102 69.6±0.127 72.8±0.106 83.7±0.100 91.3±0.086 95.7±0.066
5 36.8±0.077 39.7±0.069 47.8±0.149 61.3±0.184 66.0±0.088 72.5±0.080 80.1±0.082 88.5±0.069 89.9±0.065
10 35.0±0.085 37.6±0.069 44.7±0.085 60.4±0.078 63.4±0.106 71.2±0.074 77.5±0.064 86.1±0.092 88.2±0.077
20 21.9±0.045 34.1±0.080 39.2±0.088 56.9±0.065 59.3±0.073 66.4±0.065 72.3±0.106 77.4±0.069 81.8±0.094
30 16.5±0.074 31.5±0.066 36.4±0.131 50.7±0.085 55.5±0.066 58.3±0.082 66.9±0.063 71.6±0.085 75.1±0.094
50 15.1±0.048 24.8±0.071 29.6±0.088 42.2±0.086 47.7±0.128 51.5±0.114 57.1±0.092 56.3±0.112 70.4±0.086
100 7.2±0.053 9.5±0.131 15.1±0.131 24.3±0.094 31.6±0.069 34.1±0.090 42.6±0.086 40.8±0.069 53.7±0.236
CPS: Custom pharma service, RPM: Revolution per min, SD: Standard deviation
Table 6: Viscosity of the formulation (CPS) before gelation
Shear rate 
(RPM)
F1±SD F2±SD F3±SD F4±SD F5±SD F6±SD F7±SD F8±SD F9±SD
1 823.5±0.624 860.7±0.637 910.1±0.813 970.5±0.855 1020±0.965 1095.2±0.774 1140.9±1.256 1176.2±0.941 1201.9±1.157
5 731.2±0.920 813.4±0.605 866.5±0.790 905.6±0.800 980.6±0.883 1014.8±2.593 1092.5±0.941 1098.1±0.734 1169.2±0.454
10 668.4±0.662 735.9±0.565 768.9±1.079 882.7±0.623 941.2±1.067 910.9±1.259 954.6±0.848 1012.3±0.993 1130.7±1.061
20 612.9±0.828 691.3±0.610 750.7±0.69 727.3±0.889 813.4±0.864 766±0.951 878.1±0.711 846.8±0.637 869.4±0.571
30 508.7±0.232 530.1±0.834 615.3±1.111 591.5±0.928 638.7±1.098 705.4±0.697 791.4±0.962 718.4±0.588 796.6±0.989
50 320.1±0.836 488.8±1.224 461.4±1.096 503.1±0.920 564.3±1.098 645.2±0.509 713.1±0.828 634.6±0.588 704.9±1.256
100 75.5±0.700 160.1±0.786 178.6±0.771 165.6±1.025 201.7±0.932 212.3±1.080 245.8±0.787 289.0±1.019 318.1±1.283
CPS: Custom pharma service, RPM: Revolution per min, SD: Standard deviation
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of STF stirred at 50 rpm at 37±0.5°C. One end of the diffusion tube 
was covered by a cellophane membrane. The 1 ml formulation was 
spread on the cellophane membrane, and membrane was placed 
such that it just touches the diffusion medium STF present in the 
Fig. 8: Rheological studies of in situ gels before gelation
Fig. 6: Infrared spectra of in situ gel of moxifloxacin
Fig. 7: Thermal analysis of moxifloxacin in situ gel
receptor  compartment.  The  drug  samples  were  withdrawn at 
the  interval  of  1  h  for  the  period  of  8  h.  From  diffusion 
medium and analysed by a UV spectrophotometer at 288.5 nm using 
STF as blank (Fig. 11).
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Pharmacokinetic release studies [10]
All the optimized formulations were subjected to study the release 
kinetics, and the best fit kinetic model was determined for the optimized 
formulations (Table 9).
Antimicrobial efficacy studies [11]
The antimicrobial efficacy studies were carried out to ascertain the 
biological activity of the optimized formulations. Staphylococcus aureus 
and Escherichia coli were used as the test organisms. Antimicrobial 
efficiency was determined by agar diffusion test employing cup-plate 
method. Sterile solutions of MOX (standard solution) and the developed 
formulations were diluted at different concentration (test solutions) 
these solutions were poured into cups bored into sterile nutrient 
agar previously seeded with test organisms (E. coli and S. aureus), 
after allowing diffusion of the solutions for 2 h, the agar plates were 
incubated at 37°C for 24 h. The zone of inhibition (ZOI) measured 
around each cup and was compared with that of control. The entire 
operation except the incubation was carried out in a laminar air flow 
unit. Both positive and negative controls were maintained during the 
study (Table 10 and Fig. 12).
Accelerated stability studies [7,9]
Stability is defined as the extent, to which a product retains within 
specified limits and throughout its period of storage and uses, i.e., shelf 
life. Stability studies were carried out on optimized formulations 
according to the International Conference on Harmonization (ICH) 
guidelines.
A sufficient quantity of formulations in previously sterilized vials 
was stored in desiccators containing a saturated solution of sodium 
chloride, which gives a relative humidity of 75±5%. The desiccators 
were placed in a hot air oven maintained at a temperature 40±5°C and 
room temperature. Samples were withdrawn at 7 days interval for 
42 days. Percent drug remaining was calculated and plotted against 
time in days (Table 10 and Figs. 14 and 15).
RESULTS
Solubility study
The solubility of MOX was found to be dependent on pH. MOX was 
soluble in a cosolvent mixture of propylene glycol and water, glycerine 
and water 2.4 g of MOX soluble in 100 ml water.
Melting point determination
The	melting	point	of	MOX	was	found	to	be	approximately	238–242°C.
Table 9: Regression coefficient (r2) values of different kinetic models
Formulation % CDR Zero-order First-order Higuchi matrix Peppas plot 
r2 value “n” value
F1 98.87 0.948 0.737 0.981 0.551 0.524
F2 96.15 0.949 0.783 0.967 0.555 0.526
F3 93.68 0.933 0.931 0.993 0.541 0.500
F4 94.79 0.945 0.906 0.979 0.538 0.496
F5 91.04 0.893 0.911 0.986 0.502 0.415
F6 85.55 0.917 0.970 0.994 0.527 0.463
F7 84.05 0.879 0.965 0.980 0.485 0.474
F8 81.21 0.907 0.939 0.963 0.502 0.406
F9 77.84 0.929 0.944 0.962 0.529 0.453
CDR: ???
Table 8: Standard calibration data of MOX







SD: Standard deviation (n±3), MOX: Moxifloxacin hydrochloride
Table 7: Test of sterility
Formulation code Days of incubation
1 2 3 4 5 6 7
F1 - - - - - - -
F2 - - - - - - -
F3 - - - - - - -
F4 - - - - - - -
F5 - - - - - - -
F6 - - - - - - -
F7 - - - - - - -
F8 - - - - - - -
F9 - - - - - - -
Where “-”sign indicate the no growth. SD: Standard deviation
Fig. 9: Rheological studies of in situ gels after gelation
Fig. 10: Calibration curve of moxifloxacin hydrochloride in 
simulated tear fluid
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Fig. 12: Antimicrobial activity of eye drop and batch-F7
Table 10: Antimicrobial activity of in situ gels
Test microorganisms Diameter of the ZOI produced by  in situ 
gels and marketed eye drops (Std) (mm)
F1 F2 F3 F4 F5 F6 F7 F8 F9 Std
Staphylococcus aureus 48 47 46 48 48 47 48 48 47 37
Escherichia coli 53 53 52 53 52 52 53 53 53 37
ZOI: Zone of inhibition
Fig. 11: Comparative in vitro release of marketed eye drop and in situ gels 
Determination of λmax/UV spectrometry
λmax of MOX was found to be 288.5 in STF pH 7.4.
Drug excipients compatibility study using
FT-IR spectroscopy study
FTIR study was carried on the pure drug, a physical mixture of drug and 
polymers, formulations to confirm the compatibility of the drug with 
other excipients used in the preparation of in situ gels.
DSC
Thermal characterization of pure drug and the physical mixture 
was performed with a calorimeter. The sample was placed in sealed 
aluminum pans. The samples were scanned at 20°C/min from 20°C to 
300°C.
EVALUATION OF PREPARED IN SITU GELLING SYSTEM
Interaction studies
FTIR spectral analysis
The prepared in situ gelling systems were evaluated for interaction 
studies to ensure that there is no interaction occurred in between drug 
and polymers. For confirmation of stability of the drug in the prepared 
formulations, the IR spectra were taken and compared with that of pure 
drug. The result of these studies revealed that there were no definite 
changes obtained in the bands of the drug with respect to pure drug 
(Fig. 6).
DSC analysis of MOX
Evaluation of visual appearance, clarity, pH, and drug content
All the prepared in situ gelling systems were evaluated for preliminary 
steps such as visual appearance, clarity, pH, and drug content. These 
formulations were translucent and clear. The pH of the formulations 
was found to be 4.4, and drug content was in between 73% and100% 
(Table 4).
Rheological studies
For the development of optimum in situ gelling system, two major 
prerequisites viscosity and gelling capacity should be taken in 
consideration, since the ocular shear rate is very high ranging from 
0.03/S	 during	 inter-blinking	 periods	 to	 4250–28500/S	 during	
blinking, viscoelastic fluid with a viscosity that is high under low 
shear rate condition and low under high shear rate condition, which is 
called pseudo-plastic fluid, is often preferred, so dynamic viscosity of 
formulations was measured as the change of shear rate before and after 
gelation (Tables 5 and 6 and Figs. 8 and 9).
Sterility testing
All the prepared in situ gelling systems were evaluated for the sterility. 
After 7 days of incubation, the results showed no microbial growth in 
all formulations (Table 7).
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Fig. 13: Factorial plot
Fig. 14: Stability studies of in situ gels art room temperature
Fig. 15: Stability studies of in situ gels at 40°C
Estimation of MOX by spectrophotometric method
A simple spectrophotometric method for estimation of MOX was 
developed	in	STF,	which	exhibited	λmax at 288.5 nm. Results are shown 
in Table 8 and Fig. 10.
In vitro release studies
The in vitro release of MOX from the prepared formulations was studied 
through cellophane membrane using diffusion cell. The release studies 
of prepared in situ gelling systems were carried out up to 8 h (Fig. 11).
Antimicrobial efficacy studies
The optimized in situ gelling formulations showed antimicrobial activity 
when tested microbiologically by the cup-plate technique. Clear zones 
of inhibition were obtained in all the formulations. The diameter of ZOI 
produced by formulations against all test microorganisms is given in 
Table 10 and Fig. 12.
Final equation in terms of actual factors:
% drug release=+89.24-7.60*gelrite-3.44*sodium alginate
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Table 11: Stability studies of formulation F7
S. No Number of weeks Visual appearance Clarity pH
RT 40°C RT 40°C RT 40°C
1 0 Translucent Translucent Clear Clear 4.40±0.016 4.40±0.014
2 1 Translucent Translucent Clear Clear 4.41±0.016 4.42±0.014
3 2 Translucent Translucent Clear Clear 4.44±0.014 4.47±0.008
4 3 Translucent Translucent Clear Clear 4.42±0.008 4.43±0.021
5 4 Translucent Translucent Clear Clear 4.44±0.016 4.48±0.016
6 5 Translucent Translucent Clear Clear 4.46±0.047 4.50±0.020
7 6 Translucent Translucent Clear Clear 4.46±0.018 4.53±0.018
SD=Standard deviation (n±3)
Accelerated stability studies
According to the ICH guideline, the accelerated stability studies were 
carried for prepared in situ gelling systems. All the formulations 
were analyzed for visual appearance, clarity, pH, and drug remaining. 
6 weeks of stability studies reveal that there was no change in visual 
appearance and clarity. All the formulations showed slight changes in 
pH, but it was in acceptable limits (±0.5). Study of percentage drug 
remaining in all formulations reveals that there were no definite 
changes observed to justify for drug degradation (Table 11 and 
Figs. 14 and 15).
DISCUSSION
Optimized formulations F6 (0.1% gelrite and 1.0% sodium alginate), 
F7 (0.12% gelrite and 0.6% sodium alginate), and F8 (0.12% gelrite 
and 0.8% sodium alginate) and were liquid before instillation in to eye 
and underwent rapid gelation on instillation in to eye and had given 
85.55%, 84.05%, and 81.21% percentage cumulative drug release, 
respectively, the formulations were found to be clear, having good 
in situ gelling	capacity,	and	having	drug	content	81–100%,	optimized	
formulations were sterile and showed sustained drug release over 8 h 
period as compared to marketed eye drop, release kinetic study showed 
that the formulation followed Higuchi model diffusion controlled and 
non-Fickian release mechanism, the optimized formulations were 
having good antibacterial efficacy. As per the ICH guidelines, the 
stability study of formulations was carried out results showed that 
formulations were stable (translucent and clear) at room temperature 
as well as at 40°C.
Hence from the above results, we can conclude that F7 (0.12% 
gelrite and 0.6% sodium alginate) is the best formula (percentage 
cumulative drug release over 84.05%) and it is possible to formulate 
in situ ophthalmic gels of MOX using gelrite with sodium alginate in 
combination for the treatment of various bacterial infections.
CONCLUSION
The present work was carried out to develop ion activated in situ gel of 
MOX, a broad spectrum antibacterial agent used in the treatment of ocular 
infections, was successfully formulated as in situ gel-forming eye drops using 
gelrite as a gelling agent in combination with sodium alginate as a viscosity 
enhancing agent. Thus, the developed formulation is a viable alternative to 
conventional eye drops of its ability to sustain drug release. Furthermore, 
important is the ease of administration afforded and decreased frequency 
of administration resulting in better patient acceptance.
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